Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.45 |
| ▸ | FLT1 | P17948 | 4/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.45 |
| ▸ | FLT4 | P35916 | 4/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479352 | 0.82 | KDR (0.54) | EPHB4KDRFGFR1FLT1FGFR2 | |
| SCHEMBL6479263 | 0.78 | SYK (0.57) | EPHB4KDRFGFR1FLT1FGFR3 | |
| SCHEMBL4946510 | 0.77 | EPHB4 (0.69) | EPHB4KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL6491142 | 0.74 | FGFR1 (0.42) | KDRFGFR1FLT1FGFR2FGFR4 | |
| SCHEMBL6482909 | 0.72 | SRC (0.52) | EPHB4KDRFGFR1FLT1FGFR3 | |
| SCHEMBL6481335 | 0.69 | EPHB4 (0.55) | EPHB4KDRFGFR1FLT1AURKB | |
| SCHEMBL6479294 | 0.69 | CYP19A1 (0.48) | KDRFGFR1FLT4AURKBEGFR | |
| SCHEMBL4941396 | 0.69 | EPHB4 (0.64) | EPHB4KDRAURKBEGFRIGF1R | |
| SCHEMBL6483193 | 0.68 | KDR (0.57) | EPHB4KDRFGFR1FLT1FGFR3 | |
| SCHEMBL5493929 | 0.68 | ENPP1 (0.64) | EPHB4KDRFGFR1FLT1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | EPHB4 2420/4885KDR 4/4885FGFR1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.